Home/Get Matched/NCT06855498
Phase 3Recruiting
View on ClinicalTrials.gov

Testing povorcitinib for hidradenitis suppurativa (HS)

Official title: Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

A Phase 3b, Multicenter, Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

Condition: Hidradenitis Suppurativa (HS)Sponsor: Incyte CorporationTarget enrollment: 600
  • Phase 3
  • 1 group
  • Sites in Calgary, Edmonton and 16 more cities
  • Recruiting
Investigative Site CA023, Calgary, AlbertaInvestigative Site CA027, Edmonton, AlbertaInvestigative Site CA031, Sherwood Park, AlbertaInvestigative Site CA024, Vancouver, British ColumbiaInvestigative Site CA025, London, OntarioInvestigative Site CA032, Toronto, OntarioInvestigative Site CA009, Saint-Jérôme, QuebecInvestigative Site CA029, Verdun, QuebecInvestigative Site CA008, Calgary, AlbertaInvestigative Site CA005, Edmonton, AlbertaInvestigative Site CA003, Winnipeg, ManitobaInvestigative Site CA004, Barrie, OntarioInvestigative Site CA030, Cobourg, OntarioInvestigative Site CA002, London, OntarioInvestigative Site CA022, Markham, OntarioInvestigative Site CA016, Mississauga, OntarioInvestigative Site CA001, Peterborough, OntarioInvestigative Site CA010, Richmond Hill, OntarioInvestigative Site CA017, Toronto, OntarioInvestigative Site CA018, Toronto, OntarioInvestigative Site CA021, Toronto, OntarioInvestigative Site CA019, Waterloo, OntarioInvestigative Site CA020, Québec, QuebecInvestigative Site CA026, Québec, QuebecInvestigative Site CA015, Saskatoon, Saskatchewan

Interventions

  • Medication

    povorcitinib

    Study drug will be taken orally as defined by the protocol.

Canadian Sites (25)

17 of 25 recruiting

  • Investigative Site CA008

    Calgary, Alberta

    Recruiting

  • Investigative Site CA005

    Edmonton, Alberta

    Recruiting

  • Investigative Site CA003

    Winnipeg, Manitoba

    Recruiting

Eligibility Criteria

See who this study is looking for17 criteria

The trial’s own eligibility text, word for word from the registry. Only the trial site can say who takes part.

Inclusion

  • +Ability to comprehend and willingness to sign a written ICFInformed consentThe process of being told what taking part involves, then choosing freely.Read more → for the study.
  • +Completed the treatment period of a predetermined, Incyte-sponsored, povorcitinib parent study without safety or tolerability concerns, per investigatorPrincipal investigatorThe doctor or researcher responsible for running the study at a site.Read more →'s assessment.
  • +Received clinical benefit from treatment with study drug during the parent study, as determined by the investigator.
  • +Demonstrated compliance, as assessed by the investigator, with the parent ProtocolProtocolThe detailed plan a study must follow.Read more → requirements.
  • +Willingness and ability to comply with the study Protocol and procedures.
  • +Willingness to avoid pregnancy or fathering children as defined in the protocol.

Exclusion

  • −Known hypersensitivity or severe reaction to povorcitinib or excipients of povorcitinib and/or other products in the same class.
  • −Any condition that would, in the investigatorPrincipal investigatorThe doctor or researcher responsible for running the study at a site.Read more →'s and/or sponsorSponsorThe organisation responsible for the study overall.Read more →'s judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
  • −Had been permanently discontinued from study treatment during the parent study.
  • −Had temporary study drug interruption due to safety and/or efficacy reasons at or after the final visit of the parent study.
  • −Received at least 1 dose of either of the following therapies within the 28 days prior to starting treatment in this rollover study:
  • −Biologic immunomodulator (examples include but are not limited to adalimumab, bimekizumab, dupilumab, infliximab, nemolizumab, secukinumab).
  • −Live, attenuated vaccine.
  • −Plans for administration of a live, attenuated vaccine during this study or within 8 weeks after the last dose of study drug.
  • −Currently enrolledEnrolmentThe number of participants a study plans to include, or has included.Read more → in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.
  • −Other protocolProtocolThe detailed plan a study must follow.Read more →-defined InclusionInclusion criteriaThe things you must have or be for a study to consider you.Read more →/Exclusion CriteriaExclusion criteriaThe things that would prevent someone from taking part.Read more → may apply.
  • −Women who are pregnant (or who are considering pregnancy) or breastfeeding.
5 concepts to explore on this page · up to 1,300 pointsTap any term to learn what it means.

In plain language

Assembled directly from this trial’s registry record. Every sentence traces to a field below — nothing here is generated or interpreted.

Learning 
What this study is

This study is testing a treatment for a condition.

Phase 3Phase 3A large study comparing a treatment against the current standard.Read more → — a large study comparing this against the current standard, usually across many hospitals.

From the trial registry

Built from these fields:

  • designModule.designInfo.primaryPurpose
  • designModule.phases
Who receives what

Everyone in this study is in one group and receives povorcitinib.

From the trial registry

Built from these fields:

  • armsInterventionsModule.armGroups[].label
  • armsInterventionsModule.armGroups[].type
  • armsInterventionsModule.armGroups[].interventionNames
How the study is run

There is only one group in this study, so there is no assignment to different treatments.

This study is open-labelOpen-labelEveryone knows which treatment is being given — nothing is hidden.Read more →: everyone knows which treatment is being given, including you and the study team.

From the trial registry

Built from these fields:

  • designModule.designInfo.allocation
  • designModule.designInfo.maskingInfo.masking
Is there a placebo?

This study does not list a placeboPlaceboA dummy treatment with no active medicine, used for comparison.Read more → group.

From the trial registry

Built from these fields:

  • armsInterventionsModule.armGroups[].type
  • armsInterventionsModule.armGroups[].interventionNames
Who the study is looking for

The study lists a minimum age of 18 years, with no upper limit given.

The study is open to people of any sex.

The study does not accept healthy volunteersHealthy volunteerSomeone without the condition being studied who takes part anyway.Read more →.

These are the criteria the study lists. Only the trial siteTrial siteA hospital or clinic where a study is actually run.Read more → can decide whether someone can take part.

From the trial registry

Built from these fields:

  • eligibilityModule.minimumAge
  • eligibilityModule.sex
  • eligibilityModule.healthyVolunteers
How big and how long

The study aims to enrol about 600 people.

The study is currently expected to finish around February 2028.

The main measurement is taken over: Up to approximately 3 years.

From the trial registry

Built from these fields:

  • designModule.enrollmentInfo.count
  • statusModule.completionDateStruct.date
  • outcomesModule.primaryOutcomes[].timeFrame
What the study measures

Proportion of participants with Treatment-Emergent Adverse EventsAdverse eventAny medical problem that happens during a study, whether or not the treatment caused it.Read more → (TEAEs) — measured over Up to approximately 3 years.

From the trial registry

Built from these fields:

  • outcomesModule.primaryOutcomes[].measure
  • outcomesModule.primaryOutcomes[].timeFrame

Source: NCT06855498 on ClinicalTrials.gov. The full registry text is further down this page — this summary never replaces it.

Not medical advice. What do these terms mean?

What is being tested — in plain terms

About povorcitinibDrug

Study drug will be taken orally as defined by the protocol.

From the trial registry — its own words, unedited.

What a drug is here: A medicine — a chemical or small-molecule treatment — given as the thing being studied.

Read the full explanation → · in clinical review

Common questions

Answered from this trial’s registry record. Where the record doesn’t say, these answers say so rather than filling the gap.

Am I eligible for this trial?

Only the trial siteTrial siteA hospital or clinic where a study is actually run.Read more → can decide whether someone can take part. Concord cannot make that determination, and neither can any tool that has not examined you.

What the study lists: a minimum age of 18 years.

The full inclusionInclusion criteriaThe things you must have or be for a study to consider you.Read more → and exclusion criteriaExclusion criteriaThe things that would prevent someone from taking part.Read more → are published on this page, exactly as the study team wrote them.

The useful next step is to bring this trial to your doctor. Answering a few questions first gives them something concrete to review.

See how your details line up — get matched
From the trial registry
  • eligibilityModule.minimumAge
  • eligibilityModule.eligibilityCriteria
Is there a placebo?

This study does not list a placeboPlaceboA dummy treatment with no active medicine, used for comparison.Read more → group.

Save this trial to share with your doctor
From the trial registry
  • armsInterventionsModule.armGroups[].type
Would I know which treatment I am getting?

This study is open-labelOpen-labelEveryone knows which treatment is being given — nothing is hidden.Read more →: everyone knows which treatment is being given, including you and the study team.

There is only one group in this study, so there is no assignment to different treatments.

Save this trial to share with your doctor
From the trial registry
  • designModule.designInfo.maskingInfo.masking
  • designModule.designInfo.allocation
Who can join?

The study lists a minimum age of 18 years, with no upper limit given.

It is open to people of any sex.

It does not accept healthy volunteersHealthy volunteerSomeone without the condition being studied who takes part anyway.Read more →.

Only the trial siteTrial siteA hospital or clinic where a study is actually run.Read more → can confirm whether a particular person can take part.

See how your details line up — get matched
From the trial registry
  • eligibilityModule.minimumAge
  • eligibilityModule.sex
  • eligibilityModule.healthyVolunteers
How long would this take?

The study's main measurement is taken over: Up to approximately 3 years.

The study as a whole is currently expected to finish around 2028-02-28.

How long any one person takes part can differ from the study length. The study team can tell you what the schedule looks like in practice.

Ask the study team directly
From the trial registry
  • outcomesModule.primaryOutcomes[].timeFrame
  • statusModule.completionDateStruct.date
How many people are taking part?

The study aims to enrol about 600 people.

Save this trial to share with your doctor
From the trial registry
  • designModule.enrollmentInfo.count
Where is this happening?

This study lists 30 locations, including: Calgary, Alberta, Canada; Edmonton, Alberta, Canada; Sherwood Park, Alberta, Canada; Vancouver, British Columbia, Canada; Winnipeg, Manitoba, Canada; Barrie, Ontario, Canada, and 24 more.

Sites can open and close during a study, so confirm with the team before travelling.

Ask the study team directly
From the trial registry
  • trial_locations

About This Trial

Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.

Other Sites (15)

Investigative Site US061

Ann Arbor, Michigan, United States

Investigative Site US114

Auburn Hills, Michigan, United States

Investigative Site US120

Detroit, Michigan, United States

Investigative Site US091

Troy, Michigan, United States

Investigative Site US042

Waterford, Michigan, United States

Investigative Site US011

Minneapolis, Minnesota, United States

Investigative Site US082

East Syracuse, New York, United States

Investigative Site US034

New York, New York, United States

Investigative Site US081

New York, New York, United States

Investigative Site US065

New York, New York, United States

Investigative Site US075

New York, New York, United States

Investigative Site US050

Rochester, New York, United States

Investigative Site US132

Mill Creek, Washington, United States

Investigative Site US092

Seattle, Washington, United States

Investigative Site US003

Spokane, Washington, United States

Think this trial might be right for you?

Complete a quick intake form and we will match you with this and other relevant trials based on your medical profile.

See if this trial could fit you

This page is for informational purposes only and does not constitute medical advice. Clinical trial eligibility can only be determined by the trial site after proper screening. Trial information is sourced from ClinicalTrials.gov and may not reflect the most current status. Always consult your healthcare provider before making decisions about clinical trial participation.

HomePrivacyTerms